B. Riley Wealth Advisors Inc. Sells 12,932 Shares of Grifols, S.A. (NASDAQ:GRFS)

B. Riley Wealth Advisors Inc. lessened its holdings in Grifols, S.A. (NASDAQ:GRFS) by 22.7% during the third quarter, HoldingsChannel.com reports. The firm owned 44,018 shares of the biotechnology company’s stock after selling 12,932 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Grifols were worth $392,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in GRFS. GAMMA Investing LLC lifted its position in Grifols by 49.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after buying an additional 1,135 shares in the last quarter. Signaturefd LLC increased its position in shares of Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 2,153 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Grifols in the second quarter valued at about $89,000. HighTower Advisors LLC raised its holdings in Grifols by 12.5% during the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 1,546 shares in the last quarter. Finally, Tidal Investments LLC acquired a new position in Grifols during the third quarter valued at approximately $147,000.

Grifols Stock Performance

NASDAQ GRFS opened at $7.51 on Friday. The firm has a market capitalization of $5.16 billion, a P/E ratio of 7.74 and a beta of 0.43. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The firm’s fifty day moving average price is $8.37 and its two-hundred day moving average price is $8.10. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $12.15.

Wall Street Analyst Weigh In

Separately, Berenberg Bank raised Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.